Eli Lilly and Boehringer Ingelheim have announced Jentadueto tablets are now available by prescription in pharmacies across the U.S. Jentadueto is a new prescription medication for type 2 diabetes patients who need to control their blood sugar.  Jentadueto is a  twice daily medication combining two diabetes medicines — the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin and metformin — in one tablet. Linagliptin is marketed in the U.S. as Tradjenta 5mg once-daily tablets.  Jentadueto was approved by the U.S. Food...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults. The CHMP’s decision is now referred for final action to the European Commission, which has the authority to approve medicines for the EU. The Commission usually decides on...

The FDA has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes treatment Jentadueto (linagliptin/metformin hydrochloride), which combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet, taken twice-daily, to lower blood sugar in adults with type 2 diabetes. Jentadueto is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin...

Eli Lilly has announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles (MOSA1c study) that people with type 2 diabetes face which prevent them from reaching their ultimate treatment goals.    Despite daily treatment with insulin, many people with type 2 diabetes resist a progression of insulin therapy that could help them reach their ideal blood sugar target.  As diabetes progresses, people often need to intensify their treatment by increasing their...

Amylin Pharmaceuticals and Eli Lilly and Company have agreed to terminate their alliance for type 2 diabetes drug, BYETTA (exenatide), and resolve the outstanding litigation between the companies. As part of the agreement, Amylin will take full responsibility for the worldwide development and commercialization of exenatide, starting in the United States (U.S.) on November 30, 2011, and progressing to all markets by the end of 2013.    After nearly a decade-long partnership that achieved a number of important milestones on behalf...

The U.S. Food and Drug Administration (FDA) has approved a new use for Amylin and Eli Lilly’s type 2 diabetes drug, Byetta (exenatide) injection.  Byetta is now approved as an add-on therapy to insulin glargine (Lantus), with or without metformin and/or a thiazolidinedione (TZD), for adults with type 2 diabetes who are not achieving adequate glycemic control on insulin glargine alone. The FDA approved Byetta as an add-on therapy to Lantus following a clinical trial where patients using Byetta with insulin glargine achieved...

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments. The analyses showed that patients receiving Bydureon for the treatment of type 2 diabetes experienced improvements in composite endpoints...

The  new type 2 diabetes drug Trajenta (linagliptin 5 mg film-coated tablets) received Marketing Authorization from the European Commission for the treatment of type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea. Linagliptin is also approved for use as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.The drug, made by Boehringer...

Results from a retrospective analysis of more than 778,000 patients showed the addition of Byetta (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings were presented by Amylin and Eli Lilly in a poster session at the 71st Scientific Sessions of the American Diabetes Association in San Diego on June 25. The retrospective analysis used data from the GE Healthcare Centricity electronic medical record...

Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the 71st Scientific Sessions of the American Diabetes Association. Data from the DURATION-1 study showed that after three years, patients receiving Bydureon experienced a significant reduction in A1c (1.6 percentage points) and weight (5.1 pounds) compared to...